Abstract Lipoprotein(a) [Lp(a)] plays an important role in atherosclerosis. The amino acid sequence of apolipoprotein(a) [apo(a)] reveals an arginyl-glycyl-aspartate (RGD) tripeptide that is the consensus sequence for binding of adhesive plasma proteins of the fibrinolytic system, such as fibrinogen and von Willebrand factor, to the platelet membrane glycoprotein Ilb-IIIa (GPIIb-IIIa) complex. Therefore, we undertook the present study to further investigate the role of Lp(a) in hemostasis. Binding of 12S I-Lp(a) to a single platelet membrane-associated protein (137±6 kD) comigrating with platelet GPIIb (140 kD) was found to be specific, saturable, and Ca 2+ independent. Binding of 125 I-Lp(a) to resting human blood platelets was saturable, insensitive to temperature, and independent of the apo(a) isoform (B, SI through S3). Scatchard analysis revealed a K d of 7.2± 1.8x10"' mol/L, with 729±313 Lp(a) molecules bound per platelet. Monoclonal anti-GPIIb IgG diminished Lp(a) binding by approximately 80%, monoclonal anti-GPIIb-IIIa IgG by 60%, and antiGPIIIa IgG by just 15%.
I-Lp(a) to resting human blood platelets was saturable, insensitive to temperature, and independent of the apo(a) isoform (B, SI through S3). Scatchard analysis revealed a K d of 7.2± 1.8x10"' mol/L, with 729±313 Lp(a) molecules bound per platelet. Monoclonal anti-GPIIb IgG diminished Lp(a) binding by approximately 80%, monoclonal anti-GPIIb-IIIa IgG by 60%, and antiGPIIIa IgG by just 15%.
l23 I-Lp(a) binding was competitively T he main physiological role of platelets in the hemostatic system is to provide the initial protection against hemorrhage after an interruption of vascular integrity. Thus, whenever the continuous interior layer of vascular endothelium is interrupted, platelets become attached to exposed subendothelium. The subsequent activation of platelets and their adhesion to the fibrin network are key elements in the formation of a thrombus' -a process that involves a variety of receptor-mediated steps. Conversion of platelet membrane glycoprotein lib (GPIIb) and GPIIIa from the latent state to the GPIIb-IIIa complex provides a specific binding site for adhesive plasma proteins of the fibrinolytic system such as fibrinogen, fibronectin, von Wille-- 3 The peptide sequence arginyl-glycyl-aspartate (RGD) present in all of these proteins has been shown to be the recognition element for binding to the GPIIb-IIIa complex 4 -5 -the so-called fibrinogen receptor.
Ross and colleagues 6 have shown that platelets adhering and aggregating on a denuded arterial surface release platelet-derived growth factor, which further induces smooth muscle proliferation, an important event in the formation of fibrous plaque lesions. Based on a causative relation between hypercholesterolemia and premature atherosclerosis, the enhancement of platelet activation induced by high levels of atherogenic plasma lipoproteins, such as low-density lipoproteins (LDL), has been considered to contribute to the pathogenesis of atherosclerosis.'- 7 ' 8 The role of lipoprotein(a) [Lp(a)] in that respect remains unknown. Increased plasma levels of Lp(a) have been found to be associated with premature atherosclerosis and vascular diseases. 910 A possible explanation for the atherogenicity of this particle seems not only to be restricted to the presence of apolipoprotein (apo) B-100 but also may be due to the additional presence of glycoprotein apo(a). 10 The reported high homology of apo(a) to plasminogen"' 13 supports the hypothesis that Lp(a) might be the "missing link" between thrombogenesis and atherogenesis. able to compete with plasminogen for the same binding site on monocytoid U937 cells 14 and endothelial cells.
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Lp(a) inhibits plasminogen activation by both the bacterial activator streptokinase 16 and the physiological activator tissue-type plasminogen activator. 17 Furthermore, Lp(a) enhances plasma clot lysis 18 and exhibits high-affinity binding to fibrin, 19 fibronectin, 20 tetranectin, 21 and glycosaminoglycans. 22 A survey of the amino acid sequence of apo(a) revealed the RGD sequence located at position 3879 to 3881. 12 The presence of this tripeptide initiated the present study to investigate the interaction of Lp(a) with human blood platelets, particularly with the GPIIbHla complex.
Methods

Isolation and Purification of Plasma Lipoproteins
Plasma samples were collected in citrate or EDTA from normolipemic young healthy volunteers. LDL and high-density lipoproteins (HDL) were isolated by sequential ultracentrifugation at density intervals of 1.020 to 1.050 g/mL and 1.125 to 1.21 g/mL, respectively. 23 LDL was further purified by density gradient ultracentrifugation in an SW 41 rotor (Beckman). Lp(a) was isolated from subjects exhibiting the apo(a) isoforms B, SI, S2, and S3 according to Utermann et al. 24 Lp(a) was prepared by ultracentrifugation (density interval, 1.060 to 1.125 g/mL) followed by gel filtration on a Bio-Gel A-5M (Bio-Rad) column. 23 The purity of Lp(a) fractions was assessed by double-decker immunoelectrophoresis 23 using polyclonal anti-Lp(a) and anti-LDL antibodies. All lipoprotein concentrations are expressed in milligrams or micrograms of protein per milliliter measured by the method of Lowry et al 26 using bovine serum albumin as a standard. Preparation of apo(a) and Lp(a)~ [an LDL-like particle deprived of apo(a)] was done by reductive cleavage of intact Lp(a) with dithiothreitol as described by Armstrong et al. 27 Isolation of apo(a) and remaining apo(a)-free lipoprotein particle [Lp(a)~] was achieved by affinity chromatography on heparin-Sepharose-6 CL-B (Pharmacia).
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Radioiodination of Lipoproteins
Lp(a) and LDL (3 mg protein) were iodinated with 1 mCi [ 125 I]NaI (Amersham) according to Sinn et al 28 at 25°C using Af-bromosuccinimide as an oxidizing agent. The iodinated lipoproteins were separated from free activity on Sephadex PD-10 columns (Pharmacia) followed by exhaustive dialysis against Tyrode's solution (mmol/L: NaCl 137, KC1 2.68, NaH 2 PO 4 0.42, MgCl 2 1.7, NaHCO 3 11.9, and D-glucose 5.6, pH 7.35). The specific activity of labeled lipoprotein preparations ranged from 300 to 700 cpm/ng protein.
Preparation of Human Gel-Filtered Platelets and Gel-Filtered Platelet Membranes
Human gel-filtered platelets (GFPs) were prepared from platelet-rich plasma by column chromatography on a Sepharose 2B column (Pharmacia) equilibrated with freshly prepared Ca 2+ -free Tyrode's solution (pH 7.35, containing 0.2% human serum albumin, wt/vol) as described. 29 Platelet counts were adjusted to 200 000 GFPs per microliter by means of a Thrombocounter-C System (Coulter). 29 The resulting GFPs were lysed by sonication (60 seconds, 100 W) in 10 mmol/L phosphate-buffered saline (pH 7.35, 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L EDTA, 0.15 mol/L NaCl). 30 All subsequent isolation and purification steps of platelet membrane proteins were performed at 4°C. 30 Membrane suspensions were centrifuged at 60 OOOg, washed twice, resuspended in 10 mmol/L phosphate-buffered saline containing Triton X-100 (1%, wt/vol), and stirred for 30 minutes as described for preparation of the LDL receptor. 31 After centrifugation (60 OOOg) the clear supernatant was stored at -70°C.
Affinity Chromatography
Freshly prepared Lp(a) was coupled to cyanogen bromide activated Sepharose [15 mg Lp(a) protein per gram of dry Sepharose] according to the manufacturer's suggestions. Solubilized platelet membrane proteins (1.5 mg/5 mL) were applied to the Lp(a)-Sepharose column and recycled for a total of 160 minutes at 4°C. After washing with 100 mL tris(hydroxymethyl)aminomethane (Tris)-HCI (10 mmol/L, pH 7.4), the platelet membrane protein fraction adsorbed was eluted with 0.5 mol/L NFL.OH and immediately lyophilized.
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Lp(a) Quantitation and Apo(a) Phenotyping
Plasma concentrations of Lp(a) were quantified by electroimmunodiffusion using polyclonal anti-Lp(a) immunoglobulin G (IgG). 25 Separation of apo(a) isoforms was performed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (3.75% slab gels) using a discontinuous buffer and gel system as described. 24 Phenotyping of apo(a) was performed by means of different apo(a) isoform standards (Immuno) using polyclonal anti-apo(a) or polyclonal CRG-DGQSYRGT IgG followed by peroxidase-conjugated goat anti-rabbit IgG as described.
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Polyclonal and Monoclonal Antibodies
A 10-amino-acid apo(a) chain peptide (amino acids 3879 to 3888), the sequence of which was RGDGQSYRGT 12 plus an TV-terminal cysteine, was prepared by solid-phase synthesis on an Applied Biosystems model 9050 Prep synthesizer (Milligan) according to the method described by Merrifield. 33 Polyclonal antisera directed toward purified peptides (CRGDGQSY-RGT) coupled to keyhole limpet hemocyanin were obtained by immunization of rabbits. IgG specific for the RGD sequence of apo(a) was isolated from an (NH^SC^ precipitation of total plasma IgG by affinity purification on Lp(a)-Sepharose.
To identify platelet glycoproteins, we used monoclonal antibodies (MoAbs) against GPIIb (Dianova), GPIIb-IIIa (Dianova), and GPIIIa (Dakopatts). The antibodies were SZ.22, specific for GPIIb; J15, specific for GPIIb-IIIa; and Y2/51, specific for GPIIIa.
Ligand Blotting Experiments
GFP-derived membrane proteins (100 mg protein) eluted from Lp(a)-Sepharose were incubated in O'Ferral's buffer (3.04 mol/L glycerol, 0.17 mol/L SDS, 0.14 mol/L Tris-HCl, pH 6.8) for 20 minutes at 25°C in the absence of reducing agents. 34 SDS-PAGE of platelet membrane proteins was performed in 7% slab gels (150 V, 90 minutes) at 4°C. 25 Membrane proteins were electrophoretically transferred to nitrocellulose membranes (Millipore) at 150 mA (1.5 hours) as described. 25 After blocking in ligand blot buffer (20 mmol/L Tris, 90 mmol/L NaCl, pH 7.4, containing 2% polyvinylpyrrolidone, wt/vol), membrane strips were incubated with increasing concentrations of 123 I-Lp(a) in the presence or absence of Ca 2+ ions (2 mmol/L) for 3 hours. Membrane-bound ligands were visualized by autoradiography (Kodak X-Omat S) at -70°C. Densitometric evaluation of 123 I-Lp(a) bound to platelet membrane preparations was performed by scanning bands on a densitometer (Hirschmann Elscript 400). Competition experiments were performed in the presence of a 25-to 100-fold excess of the competing ligands. Identification of platelet GPIIb and GPIIIa blotted to nitrocellulose was performed by a Western blotting technique using MoAbs SZ.22 or Y2/51 followed by peroxidase-conjugated rabbit anti-mouse IgG (Sigma).
Binding of Iodinated Lipoproteins to Resting GFPs
GFPs, adjusted to a final concentration of 1x10' to 1x10*/ mL, were incubated with increasing amounts of 12 2+ -free Tyrode's solution in conical 1.5-mL polypropylene tubes as described by Curtiss and Plow. 33 Tubes were centrifuged for 3 minutes at 13 000 rpm and immediately frozen in liquid nitrogen. The conical tips of the tubes were amputated, and the radioactivity contained in the pellets was quantified in a gamma counter (LKB). Competition experiments were performed at 25-to 50-fold excess of the competing ligands, eg, unlabeled Lp(a), LDL, HDL,, fibrinogen, or RGD tripeptide (Bachem). Inhibition of Lp(a) binding to platelets was followed by coincubation of l23 I-Lp(a) with MoAbs (SZ.22, J15, Y2/51) or preincubation of l23 I-Lp(a) with intact anti-CRGDGQSYRGT IgG or anti-CRGDGQSYRGT IgG F(ab') 2 fragments. The latter was purified by enzymatic digestion of anti-CRGDGQSYRGT IgG with pepsin as described. 36 The F(ab') 2 fragment was extensively purified to ensure the absence of residual IgG or Fc fragments.
Results
Binding of LDL and Lp(a) to Intact, Resting GFPs
Binding of 125 I-labeled Lp(a) to unstimulated GFPs in the presence or absence of a 50-fold excess of unlabeled Lp(a) is presented in Fig 1 (left) . Binding to nonactivated GFPs was saturable and specific. The binding curves of l25 I-Lp(a) to GFPs at 25°C (Fig 1, left) and 37°C (data not shown) were similar. Scatchard analysis of the data could be interpreted in terms of a straight line with a correlation coefficient of .978 (Fig 1, left  inset ). Binding experiments with seven different Lp(a) preparations yielded a K^ value of 7.2± 1.8x10"' mol/L, with 729±313 Lp(a) particles bound per platelet, assuming a molecular mass of 5X10 3 kD for Lp(a) and a protein content of 30% (wt/wt). There was no significant difference between Lp(a) preparations with different apo(a) isoforms (B, SI through S3) with respect to binding of 125 I-Lp(a) to platelets. Control experiments using 125 I-labeled LDL (n=3) also revealed saturable and specific binding to nonactivated GFPs at 25°C (Fig  1, right) , with a Ka value of 6.0±2.1xl0~8 mol/L and 2940+860 molecules LDL per platelet (as calculated from the Scatchard plot, Fig 1, right inset) , assuming a molecular mass of 2X10 3 kD and a protein content of 20% (wt/wt) for LDL. Further studies have shown that Lp(a)~ (an LDL-like particle) binds to an extent similar to that of LDL.
To determine whether LDL or HDL3, lipoproteins known to bind to resting platelets, 35 -3741 or fibrinogen (containing an RGD sequence, see Reference 5) interferes with Lp(a) binding, we carried out competition experiments of Lp(a) binding. Both fibrinogen and unlabeled Lp(a) were observed to inhibit 90% of the binding of 125 I-Lp(a) by platelets when present in a 20-fold excess (Fig 2) . LDL and HDL3, on the other hand, exhibited a lower displacement capability of 12i I-Lp(a) of a maximum of 76%. Plotting percentage binding of 12i I-Lp(a) versus the molar ratio of competing ligands, one can deduce that LDL, but more likely HDLj, is a weaker competitor than fibrinogen or unlabeled Lp(a) (Fig 2, inset) .
Identification of Lp(a)-Binding Proteins on Intact GFPs and in Isolated Platelet Membrane Proteins
To identify the protein or proteins responsible for Lp(a) binding to platelets, we partially purified Triton X-100-solubilized platelet membrane proteins by affin- ity chromatography on Lp(a)-Sepharose and subjected them to SDS-PAGE. In five independent ligand blotting experiments using different 125 I-Lp(a) and platelet membrane protein preparations, under nonreducing electrophoretic conditions, a single Lp(a) binding protein with an apparent molecular mass of 137±6 kD that comigrated with GPIIb was identified (Fig 3a, lane A) . Incubation of identically prepared nitrocellulose strips with MoAb SZ.22 directed against GPIIb revealed the presence of GPIIb (140 kD, under nonreducing conditions) in the platelet membrane protein fraction eluted from the Lp(a) affinity column (Fig 3a, lane B) . In affinity-purified platelet membrane protein fractions, GPIIIa was not detected by Western blot experiments using a specific MoAb (Y2/51) (Fig 3a, lane C) . The observed interaction of Lp(a) with the 137±6-kD protein showed saturable binding characteristics in ligand blots (Fig 3b) and could be competitively inhibited by increasing amounts of unlabeled Lp(a) to an extent similar to that observed when intact GFPs were used (Fig 2) . It is of interest that under these experimental conditions (SDS-PAGE followed by blotting), I-LDL to the 137±6-kD protein when Ca 2+ ions were present in the assay system indicated divalent ion independence of these interactions (data not shown).
With the use of unlabeled LDL as a competitor, a strong displacement of 125 I-Lp(a) was observed in ligand blotting experiments (Fig 4, lanes b and c) . In contrast to LDL, HDL3 was unable to compete for '"I-Lp(a) (Fig  4, lanes d and e) , although both lipoproteins were effective to the same degree in displacing 125 I-Lp(a) on intact, resting platelets (Fig 2) .
To further investigate whether binding of IgG), whereas treatment with J15 (anti-GPIIb-IIIa IgG) led to an inhibition of 45% to 65%. In two of the four experiments a slight diminution (5% to 18%) of 
Binding of Lp(a) Is Not Mediated by the RGD Sequence Present in Apo(a)
To further investigate whether the RGD peptide motif present in the various apo(a) isoforms investigated (Fig 6) was responsible for mediating Lp(a) binding to platelet GPIIb and/or intact GPIIb-IIIa complex, we preincubated GFPs with increasing concentrations of isolated RGD peptides before measuring Lp(a) binding. Even when present at a molar excess of 50:1 over the amount of Lp(a) present, prior incubation with RGD peptides did not affect the binding capacity of labeled Lp(a) to intact GFPs (Fig 7) . Consistent with that observation, when (Fig 8B and 8C) or polyclonal anti-CRGDGQSYRGT F(ab')2 fragments (Fig 8F, 8G , and 8H) before Lp(a) binding was measured, neither intact anti-CRGDGQSYRGT IgG nor anti-CRGDGQSYRGT F(ab') 2 fragments significantly influenced 12i I-Lp(a) binding when compared with IgG (Fig 8D and 8E) or the corresponding F(ab') 2 fragments that did not recognize the RGD motif. From this set of experiments, it must be concluded that binding of Lp(a) to intact, resting GFPs is not mediated via the RGD sequence, even when Ca 2+ ions are present in the assay system.
Discussion
Lp(a), a well-known risk factor in the development of atherosclerosis, also may play an important role during thrombogenesis. For this reason we investigated the binding of Lp(a) to platelets. Our experiments revealed a strong interaction between Lp(a) and intact,, resting platelets (Fig 1, left) . This binding, with a K a value of 7.2+1.8x10"' mol/L (729±313 molecules bound per platelet), was 5 to 10 times stronger than the binding of LDL (1^=1.6 to 5.1 xlO" 8 mol/L, B m «=1348 to 7074 molecules per platelet) and HDL (A^=l.l to 8xlO~8 mol/L, 8^=1585 to 4200 molecules per platelet) to platelets that has been observed by others. 35 -3741 Our own data (Fig 1, right) on LDL binding (2940±860 molecules LDL per platelet, X d =6.0±2.1xl0" 8 mol/L) were in good agreement with these studies. Binding of Lp(a) was competitively inhibited by fibrinogen and unlabeled Lp(a) to the same degree, whereas LDL and HDL were much weaker competitors for platelet-bound Lp(a) (Fig 2) . Thus, the question remained: What is the actual binding site of Lp(a) to platelets?
Evidence presented in Figs 3 and 5 suggests that GPIIb (140 kD) contributes most to the specific, high-affinity binding of Lp(a) to isolated platelet membrane protein fractions. Previous findings revealed that the binding of LDL and HDL3 to platelets occurs via three different platelet membrane proteins with apparent molecular masses of 156,130, and 115 kD. 34 Hassall et al 38 reported only a single 140-kD binding protein for LDL. The observed heterogeneity in molecular mass of the putative target protein(s), 34 ILp(a) to platelets is independent of divalent ions all strengthen the hypothesis that lipoprotein binding sites on platelets differ from the "classic" receptor of nucleated cells (160 kD). A recent study found that preincubation of platelets with monoclonal anti-LDL receptor IgG failed to inhibit the subsequent binding of LDL, clearly indicating that proteins, other than the apo B/E receptor, serve as binding sites for lipoproteins on platelets. 41 Koller et al 40 first identified GPIIb and GPIIIa as the platelet membrane proteins responsible for binding of LDL and HDL,. These authors further observed binding of LDL and HDL3 to GPIIb and GPIIIa under nonreducing and reducing conditions (using SDS-PAGE). In addition, a 50% inhibition of binding of either LDL or HDL3 to the GPHb-HIa complex on intact, resting platelets was observed in the presence of anti-GPIIIa IgG. 40 A less-pronounced effect was observed when binding of HDL or LDL was investigated in the presence of anti-GPIIb IgG. Finally, the same authors 40 observed that fibrinogen, which is known to bind to GPIIIa, 5 is also able to displace GPIIb-bound lipoproteins in ligand blot experiments.
As presented in this report, the situation for binding of Lp(a) to intact human platelets seems to be somewhat different when compared with LDL and HDL. In our experiments (Fig 5) , anti-GPIIIa IgG acted only as a weak binding inhibitor, whereas anti-GPIIb IgG was able to decrease binding of 125 I-Lp(a) in a dose-dependent manner up to 90% of control values. These differences in binding properties between LDL 40 and Lp(a) (Fig 2) suggested that the apo(a) molecule might be responsible for this increment affinity for Lp(a) binding. A direct proof of this assumption was not possible, as we failed to obtain high-affinity specific binding to platelets using purified apo(a). This is probably because of the presence of reducing agents during the preparation of apo(a), 27 which might lead to an extensive disruption of intrakringle disulfide bonds, causing unphysiological rearrangement of the apo(a) tertiary structure. Our experiments, however, have shown that Lp(a)~ binds to an extent similar to that observed for LDL. Recently, Ezratty and colleagues 42 reported 81 000±23 000 Lp(a) molecules bound per platelet. This seems high and might be a result of the low molecular masses for Lp(a) (914 kD) and LDL (550 kD) used in their calculations, which are in sharp contrast to the molecular masses published by others. 43 " 45 We have found that binding of Lp(a) to GFPs is mediated via GPIIb to isolated platelet membrane protein fractions in ligand blotting experiments similar to that reported for LDL binding. 40 We additionally observed that binding of Lp(a) to platelets is independent of the apo(a) isoform. Thus, it seems likely that a common domain present in all the various apo(a) isoproteins is responsible for the binding of different Lp(a) preparations to platelets. Therefore, we speculated that an RGD tripeptide might be responsible for this increment affinity for Lp(a) to resting platelets and to GPIIbIlla in particular. First, LDL, Lp(a)~ [an LDL-like particle prepared from Lp(a) as described in "Methods"], and HDL are bound by GFPs with an affinity (Kt value) approximately one order of magnitude lower than observed for intact Lp(a). Second, the RGD sequence is present in neither apo B-100 nor the various HDL apolipoproteins or human plasminogen, which shares high homology to Lp(a). 10 Using polyclonal anti-CRG-DGQSYRGT IgG directed against the sequence of apo(a) (position 3879 to 3888) published by McLean et al, 12 we could identify this particular sequence by a Western blot technique in all Lp(a) preparations tested (Fig 6) . Thus, it was conceivable that the RGD tripeptide of intact Lp(a) also might be exposed for recognition by the GPIIb-IIIa complex, which is also present on resting platelets. 5 However, the present findings (Figs 7 and 8 ) clearly demonstrate that the RGD peptide motif of apo(a) is not required for Lp(a) binding by platelet GPIIb-IIIa in vitro as found for the various adhesive proteins of the fibrinolytic system. 5 Our data on GPIIb as a main Lp(a) binding protein are supported by recent findings that GFPs isolated from normolipidemic and thrombasthenic platelets (lacking GPIIb-IIIa) have a comparable number of Lp(a) binding sites on resting ( B^, 81 000+22 000) and stimulated (B^,, approximately 40 000) platelets. 42 However, in several thrombasthenic patients characterized by a complete absence of surface-expressed GPIIbIIIa, certain amounts of GPIIb and GPIIIa or GPIIIa alone have been detected by immunoblotting, 4 * findings compatible with our results and suggesting that GPIIb and not the intact GPIIb-IIIa complex is the main binding protein for Lp(a) to platelets.
In summary, we present evidence that GPIIb is the main Lp(a)-binding protein on intact platelets and isolated platelet membrane proteins. As shown in binding experiments with intact resting GFPs, the Lp(a) binding affinity is approximately one order of magnitude higher compared with LDL and HDL. However, the responsible Lp(a) binding motif is not an RGD sequence present on the various apo(a) isoforms. Nevertheless, our results obtained from in vitro experiments further support the important role of Lp(a) in fibrinolysis and hemostasis, although GPIIb-IIIa apparently may not act as a receptor for platelet-Lp(a) interactions. The significance of our findings with respect to GPIIb (Fig 3) , however, remains to be shown in a suitable experimental model in vivo. The ability of fibrinogen to compete with 125 I-Lp(a) for binding to platelets that was observed in the present study (Fig 2) may be relevant when plasma concentrations of both proteins are increased in hyperlipidemic stages. 47 
